clinical trial · NCT03439137
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Hemodialysis Dependent Chronic Kidney DiseaseMT-6548Darbepoetin alfaMT-6548-matching placeboDarbepoetin alfa-matching placebo
brief summary
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
started
Feb 14, 2018
primary completion
Dec 12, 2018
completion
Jul 16, 2019
last updated
Apr 6, 2026
official title
A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol